Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Pegylated interferon (peginterferon) and ribavirin is the current standard therapy for chronic hepatitis C. The aims of this study were to evaluate the efficacy of peginterferon and ribavirin and to identify predictors of a sustained virological response (SVR) to the retreatment of chronic hepatitis C in Korea. Methods: The clinical records of 91 patients with chronic hepatitis C who were retreated with peginterferon and ribavirin were retrospectively analyzed. None of the patients had previously attained a SVR, and the patients were categorized according to their previous responses (nonresponder, relapser, or inadequate treatment)to conventional interferon/ribavirin. Results: The overall SVR rate was 54.9%. Independent predictors of a SVR were genotypes 2 and 3, relapse, an adherence to peginterferon of over 80%, and an early virological response (EVR). For genotype 1 patients, an adherence to peginterferon of over 80% was an independent predictor of a SVR. Conclusions:Peginterferon and ribavirin therapy is effective for the retreatment of Korean chronic hepatitis C patients who have failed interferon/ribavirin, especially in patients with genotypes 2and 3, relapse, an adherence to peginterferon over 80%, and an EVR. For genotype 1 patients, retreatment was effective in patients with an adherence to peginterferon over 80%.
Abstract
Background/Aims: Pegylated interferon (peginterferon) and ribavirin is the current standard therapy for chronic hepatitis C. The aims of this study were to evaluate the efficacy of peginterferon and ribavirin and to identify predictors of a sustained virological response (SVR) to the retreatment of chronic hepatitis C in Korea. Methods: The clinical records of 91 patients with chronic hepatitis C who were retreated with peginterferon and ribavirin were retrospectively analyzed. None of the patients had previously attained a SVR, and the patients were categorized according to their previous responses (nonresponder, relapser, or inadequate treatment)to conventional interferon/ribavirin. Results: The overall SVR rate was 54.9%. Independent predictors of a SVR were genotypes 2 and 3, relapse, an adherence to peginterferon of over 80%, and an early virological response (EVR). For genotype 1 patients, an adherence to peginterferon of over 80% was an independent predictor of a SVR. Conclusions:Peginterferon and ribavirin therapy is effective for the retreatment of Korean chronic hepatitis C patients who have failed interferon/ribavirin, especially in patients with genotypes 2and 3, relapse, an adherence to peginterferon over 80%, and an EVR. For genotype 1 patients, retreatment was effective in patients with an adherence to peginterferon over 80%.
참고문헌 (36)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Hadziyannis SJ, "Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose", Ann Intern Med, 140, pp.346~355 (2004)
- Poynard T, "Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group", Hepatology, 31, pp.211~218 (2000)
- Shiratori Y, "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy", Ann Intern Med, 132, pp.517~524 (2000)
- Sobesky R, "Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group", Gastroenterology, 116, pp.378~386 (1999)
- Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
- Veldt BJ, "Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis", Ann Intern Med, 147, pp.677~684 (2007)
- Shiffman ML, "Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment", Gastroenterology, 126, pp.1015~1023 (2004)
- Poynard T, "Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa", ribavirin therapy, 2009, pp.136, 1618~1628
- Ghany MG, "American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update", Hepatology, 49, pp.1335~1374 (2009)
- Krawitt EL, "Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C", J Hepatol, 43, pp.243~249 (2005)
- Parise E, "Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy", Braz J Infect Dis, 10, pp.11~16 (2006)
- Sherman M, "Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy", Gut, 55, pp.1631~1638 (2006)
- Taliani G, "Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients", Gastroenterology, 130, pp.1098~1106 (2006)
- Basso M, "Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients", Dig Liver Dis, 39, pp.47~51 (2007)
- Jacobson IM, "A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C", Am J Gastroenterol, 100, pp.2453~2462 (2005)
- Goncales FL Jr, "Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?", BMC Infect Dis, 10, pp.212~ (2010)
- Trapero-Marugan M, "Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment", J Clin Pharm Ther, 36, pp.695~703 (2011)
- Husa P, "Efficacy and safety of peginterferon alpha-2a (40 kD) plus ribavirin among patients with chronic hepatitis C and earlier treatment failure to interferon and ribavirin: an open-label study in central and Eastern Europe", Eur J Gastroenterol Hepatol, 23, pp.375~381 (2011)
- Diago M, "Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients", Aliment Pharmacol Ther, 26, pp.1131~1138 (2007)
- Cheruvattath R, "Pegylated interferon and ribavirin failures: is retreatment an option?", Dig Dis Sci, 52, pp.732~736 (2007)
- Maynard M, "Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI)", J Hepatol, 44, pp.484~490 (2006)
- Mathew A, "Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment", Dig Dis Sci, 51, pp.1956~1961 (2006)
- Ciancio A, "A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin", Aliment Pharmacol Ther, 24, pp.1079~1086 (2006)
- Yu ML, "Treatment of chronic hepatitis C in Asia: when East meets West", J Gastroenterol Hepatol, 24, pp.336~345 (2009)
- Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
- Tanaka Y, "Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C", Nat Genet, 41, pp.1105~1109 (2009)
- Honda M, "Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C", Gastroenterology, 139, pp.499~509 (2010)
- Sinn DH, "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients", J Gastroenterol Hepatol, 26, pp.1374~1379 (2011)
- Camma C, "Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis", J Hepatol, 51, pp.675~681 (2009)
- Jensen DM, "Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial", Ann Intern Med, 150, pp.528~540 (2009)
- Moucari R, "High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy", J Hepatol, 46, pp.596~604 (2007)
- McHutchison JG, "Telaprevir for previously treated chronic HCV infection", N Engl J Med, 362, pp.1292~1303 (2010)
- Bacon BR, "Boceprevir for previously treated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1207~1217 (2011), N Engl J Med
- European Association for the Study of the Liver, "EASL Clinical Practice Guidelines: management of hepatitis C virus infection", J Hepatol, 55, pp.245~264 (2011)